Search Result

Results for "

Human genome

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (3) DNA/RNA Synthesis (4) Drug Derivative (1) Drug Metabolite (3) HDAC (1) HIV (3) HIV Protease (3) HSV (1) Nucleoside Antimetabolite/Analog (3) Opioid Receptor (2)
By Research Areas:	Cancer (1) Infection (4) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	Nucleotide Analogs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19627A

Naldemedine tosylate 1 Publications Verification S-297995 tosylate	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (K_i=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-P5307

Peptide A5K INF7-A5K-TAT	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-137697D

ddCTP trisodium solution (100 mM)	HIV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Drug Metabolite HIV Protease	Infection
ddCTP trilithium solution (100 mM) is a chain-terminating dideoxynucleotide. ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-E70098

RNase H2	Others	Cancer
RNase H2 is the predominant source of RNase H activity in mammalian and human cells. RNase H2 protects genome integrity. RNase H2 has been associated with ribonucleotide removal from genomic DNA in yeast and mouse, where it is required for embryonic development .

HY-19627

Naldemedine S-297995	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-137697

ddCTP	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis HIV Protease HIV Drug Metabolite	Infection
ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-P5307A

Peptide A5K acetate INF7-A5K-TAT acetate	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-P10999

INF7TAT-P55 P55	Drug Derivative Biochemical Assay Reagents	Others
INF7TAT-P55 (P55) is a polypeptide derived from INF7TAT (HY-P11000) with G1K, G20L and Y22N mutations. INF7TAT-P55 serves as a delivery carrier to deliver preassembled CRISPR ribonucleases into cells for genome editing .

HY-174252

HSV-1/HSV-2-IN-3	DNA/RNA Synthesis HSV	Infection
HSV-1/HSV-2-IN-3 inhibits the herpes-simplex-virus (HSV) helicase-primase complex, blocking the coordinated DNA-unwinding and primer-synthesis steps required for viral genome replication. HSV-1/HSV-2-IN-3 exhibits an EC₅₀ of 7.0 nM against HSV-2 in a gD-immunofluorescence cell assay containing 2 % FBS and 57.5 nM when 10 % human serum is present. HSV-1/HSV-2-IN-3 achieves an EC₅₀ of 1.1 nM in a qPCR replication assay. HSV-1/HSV-2-IN-3 shows strong selectivity over human carbonic-anhydrase off-targets (IC₅₀ ≈ 2.9 µM for hCA II and > 35 µM for hCA I). HSV-1/HSV-2-IN-3 can be studied in anti-HSV research .

HY-137697B

ddCTP trilithium	HIV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Drug Metabolite HIV Protease	Infection
ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-120106

BG14	HDAC	Others
BG14 is a chemical optical modulation of epigenetic regulation of transcription (COMET) probe. BG14 enables high-resolution optical control of epigenetic mechanisms using visible light and can photochromically inhibit human histone deacetylases (HDACs). BG14 can be used to study the dynamic regulation of the human genome .

Cat. No.	Product Name

HY-L030

Human Endogenous Metabolite Compound Library	795 compounds
The composition of endogenous metabolite compounds is affected by the upstream influence of the proteome and genome as well as environmental factors, lifestyle factors, medication, and underlying disease. Therefore, metabolites have been described as proximal reporters of disease because their abundances in biological specimens are often directly related to pathogenic mechanisms. In more recent years, metabolomics approach has been adopted or suggested to be used in various research areas including drug discovery, neurosciences, agriculture, food and nutrition, and environmental sciences. MCE owns a unique collection of 795 human endogenous metabolites, all of which are derived from human issues. This library is a powerful tool for metabonomics research and metabolism-related drug discovery.

Human Endogenous Metabolite Compound Library

795 compounds

The composition of endogenous metabolite compounds is affected by the upstream influence of the proteome and genome as well as environmental factors, lifestyle factors, medication, and underlying disease. Therefore, metabolites have been described as proximal reporters of disease because their abundances in biological specimens are often directly related to pathogenic mechanisms. In more recent years, metabolomics approach has been adopted or suggested to be used in various research areas including drug discovery, neurosciences, agriculture, food and nutrition, and environmental sciences.

MCE owns a unique collection of 795 human endogenous metabolites, all of which are derived from human issues. This library is a powerful tool for metabonomics research and metabolism-related drug discovery.

HY-L006

GPCR/G Protein Compound Library	3,389 compounds
GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery. MCE provides a unique collection of 3,389 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

GPCR/G Protein Compound Library

3,389 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provides a unique collection of 3,389 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

HY-L149

Membrane Protein-targeted Compound Library	7,678 compounds
A membrane protein is a protein molecule that is attached to or associated with the membrane of a cell or an organelle. Membrane proteins can be classified into two groups based on how the protein is associated with the membrane: integral membrane proteins and peripheral membrane proteins. In humans, about 30% genome encodes membrane proteins. Membrane proteins perform a variety of functions vital to the survival of organisms, for example, signal transduction, molecules or ion transportation, enzymatic catalysis, and intercellular communication. Membrane proteins also play important roles in drug discovery. As reported, more than 60% of current drug targets are membrane proteins. MCE supplies a unique collection of 7,678 compounds targeting a variety of membrane proteins. MCE Membrane Protein-targeted Compound Library can be used for membrane protein-focused screening and drug discovery.

Membrane Protein-targeted Compound Library

7,678 compounds

A membrane protein is a protein molecule that is attached to or associated with the membrane of a cell or an organelle. Membrane proteins can be classified into two groups based on how the protein is associated with the membrane: integral membrane proteins and peripheral membrane proteins. In humans, about 30% genome encodes membrane proteins. Membrane proteins perform a variety of functions vital to the survival of organisms, for example, signal transduction, molecules or ion transportation, enzymatic catalysis, and intercellular communication. Membrane proteins also play important roles in drug discovery. As reported, more than 60% of current drug targets are membrane proteins.

MCE supplies a unique collection of 7,678 compounds targeting a variety of membrane proteins. MCE Membrane Protein-targeted Compound Library can be used for membrane protein-focused screening and drug discovery.

HY-L230

FDA Kinase Inhibitor Library	329 compounds
Kinases are enzymes that catalyze the addition of phosphate groups to substrate molecules, a process known as phosphorylation. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes, including cell division, metabolism, and signal transduction. The human genome encodes over 500 kinases, which collectively regulate approximately 50% of cellular functions. Due to their pivotal roles, kinases represent one of the most important target classes in drug development. Kinase inhibitors can selectively block the activity of disease-associated kinases, making them valuable therapeutics for conditions such as cancer and inflammatory diseases. FDA-approved kinase inhibitors have undergone extensive preclinical and clinical studies, demonstrating high bioactivity, favorable safety profiles, and good bioavailability, rendering them suitable for investigating new therapeutic indications.

FDA Kinase Inhibitor Library

329 compounds

Kinases are enzymes that catalyze the addition of phosphate groups to substrate molecules, a process known as phosphorylation. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes, including cell division, metabolism, and signal transduction. The human genome encodes over 500 kinases, which collectively regulate approximately 50% of cellular functions. Due to their pivotal roles, kinases represent one of the most important target classes in drug development.

Kinase inhibitors can selectively block the activity of disease-associated kinases, making them valuable therapeutics for conditions such as cancer and inflammatory diseases. FDA-approved kinase inhibitors have undergone extensive preclinical and clinical studies, demonstrating high bioactivity, favorable safety profiles, and good bioavailability, rendering them suitable for investigating new therapeutic indications.

HY-L009

Kinase Inhibitor Library	3,849 compounds
Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. Kinase inhibitor library designed by MCE contains 3,849 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Kinase Inhibitor Library

3,849 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3,849 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Cat. No.	Product Name	Type

HY-137697

ddCTP	Biochemical Assay Reagents
ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

ddCTP

Biochemical Assay Reagents

ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

Cat. No.	Product Name	Target	Research Area

HY-P5307

Peptide A5K INF7-A5K-TAT	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-P5307A

Peptide A5K acetate INF7-A5K-TAT acetate	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-P10999

INF7TAT-P55 P55	Drug Derivative Biochemical Assay Reagents	Others
INF7TAT-P55 (P55) is a polypeptide derived from INF7TAT (HY-P11000) with G1K, G20L and Y22N mutations. INF7TAT-P55 serves as a delivery carrier to deliver preassembled CRISPR ribonucleases into cells for genome editing .

Species:	Virus (3)
Tag:	His (1) Tag Free (1) GST (1)
Source:	sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701920

	3C protease Protein, Human rhinovirus 14 genome polyprotein	Virus	E. coli
	The 3C protease protein forms an icosahedral capsid with the VP2 and VP3 proteins, with a diameter of 300 angstroms. 3C protease Protein, Human rhinovirus 14 is the recombinant Virus-derived 3C protease protein, expressed by E. coli , with tag free.

HY-P701921

	3C protease Protein, Human rhinovirus 14 (GST) genome polyprotein	Virus	E. coli
	The 3C protease protein forms an icosahedral capsid with the VP2 and VP3 proteins, with a diameter of 300 angstroms. 3C protease Protein, Human rhinovirus 14 (GST) is the recombinant Virus-derived 3C protease protein, expressed by E. coli , with N-GST labeled tag.

HY-P704580

	Enterovirus 71 VP0 Protein (Sf9, His) genome polyprotein; Human enterovirus 71 (strain USA/BrCr/1970) (EV71) (EV-71)	Virus	sf9 insect cells
	The enterovirus 71 VP0 protein forms a 300 angstrom icosahedral capsid with the VP2 and VP3 proteins. Enterovirus 71 VP0 Protein (Sf9, His) is the recombinant virus-derived Enterovirus 71 VP0 protein, expressed by sf9 insect cells, with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-137697D

ddCTP trisodium solution (100 mM)		Nucleotide Analogs
ddCTP trilithium solution (100 mM) is a chain-terminating dideoxynucleotide. ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-137697

ddCTP		Nucleotide Analogs
ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.